Progyny Inc
NASDAQ:PGNY

Watchlist Manager
Progyny Inc Logo
Progyny Inc
NASDAQ:PGNY
Watchlist
Price: 24.04 USD -0.46% Market Closed
Market Cap: 2.1B USD

Progyny Inc
Investor Relations

In a world where the concept of family is continually evolving, Progyny Inc. emerges as a pioneer, reshaping the landscape of fertility and family-building benefits. Founded with a mission to offer comprehensive fertility solutions, the company leverages a unique combination of personalized concierge service and cutting-edge technology to meet the growing demand for reproductive health services. Progyny's role in the industry is substantial, providing a suite of tailored benefits that include fertility treatments, egg freezing, genetic testing, and support services. Through its proprietary Smart Cycle plan, Progyny stands apart by integrating these services into a single, streamlined benefits package, reducing complexities and elevating the experience for patients and employers alike.

The heart of Progyny's business model lies in its collaboration with employers, offering them the opportunity to include comprehensive fertility benefits as part of their health packages. By doing so, Progyny opens the door for companies to attract and retain talent in a competitive workforce, ensuring employees have access to vital reproductive assistance. The company generates revenue by partnering with these employers, who pay for the fertility benefits as part of their employee health plans. This innovative approach not only ensures recurring income for Progyny but also aligns the company’s success with positive health outcomes for its clients. As more organizations recognize the value in supporting employees' family-building journeys, Progyny’s influence and relevance in the market continue to grow, reinforcing its standing as a leader in fertility solutions.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 6, 2025
AI Summary
Q3 2025

Strong Quarter: Progyny delivered third quarter revenue and profitability above the high end of guidance, continuing its streak of outperforming expectations.

Guidance Raised: For the third consecutive quarter, the company increased its full-year revenue guidance, now more than $70 million above the original midpoint.

Client Growth: Added over 80 new clients and about 900,000 covered lives for the upcoming season, highlighting strong demand despite a slower start to the selling season.

Retention & Upsell: Achieved near 100% renewal rate for existing clients in 2026, with nearly 30% expanding their benefits.

Product Expansion: Announced a first-of-its-kind supplemental plan for fertility and family building targeting small and midsized businesses and expanded global offerings.

Share Repurchase: Introduced a new $200 million share buyback program, citing strong cash flow and belief that shares are undervalued.

Cash Generation: Generated over $50 million in operating cash flow for the quarter and a record $156 million year-to-date.

Key Financials
Revenue
$1.263B to $1.278B
Operating Cash Flow
$50M (Q3); $156M (first 9 months)
Gross Margin
23%
Adjusted EBITDA Margin
17.5%
Adjusted EBITDA
$216M to $220M (full year guidance); $45.3M to $49.3M (Q4 guidance)
Net Income
$58.5M to $61.5M (full year guidance); $12.5M to $15.5M (Q4 guidance)
Earnings Per Share
$0.65 to $0.68 (full year guidance); $0.14 to $0.17 (Q4 guidance)
Adjusted EPS
$1.79 to $1.82 (full year guidance); $0.37 to $0.40 (Q4 guidance)
CapEx
$4.7M (Q3)
Working Capital
$412M (as of September 30)
Cash, Cash Equivalents, and Marketable Securities
$345M (as of September 30)
Covered Lives Added
900,000
Clients Added
Over 80
Share Repurchase Program
$200M authorized
Earnings Call Recording
Other Earnings Calls

Management

Mr. David J. Schlanger J.D.
Executive Chairman
No Bio Available
Mr. Peter Anevski CPA
CEO & Director
No Bio Available
Mr. Michael Sturmer
President
No Bio Available
Ms. Allison Swartz
Executive VP, General Counsel & Secretary
No Bio Available
Mr. Steven Leist
Chief Technology Officer
No Bio Available
Mr. James Hart
Vice President of Investor Relations
No Bio Available
Ms. Risa Fisher
Chief Marketing Officer
No Bio Available
Ms. Cassandra Pratt
Chief Human Resources Officer
No Bio Available
Ms. Julie Stadlbauer
Chief Business Development Officer
No Bio Available
Ms. Janet Choi M.D.
Member of the Medical Advisory Board & Chief Medical Officer
No Bio Available

Contacts

Address
NEW YORK
New York City
1359 Broadway, 2Nd Floor
Contacts
+12128883124.0
www.progyny.com